



O-GlcNAcylation and Cancer

Guest Editors:

**Prof. Dr. Ikram El Yazidi-
Belkoura**

Université Lille, CNRS, UMR 8576
—UGSF—Unité de Glycobiologie
Structurale et Fonctionnelle,
Lille, France

Prof. Dr. Tony Lefebvre

Université Lille, CNRS, UMR 8576
—UGSF—Unité de Glycobiologie
Structurale et Fonctionnelle,
Lille, France

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editors

Cancer is one of the leading causes of morbidity and mortality worldwide, linked in part to deteriorating environmental conditions and unsafe lifestyles. Much progress has been made in recent decades in deciphering the etiology, origin, and causes of cancer, but much remains to be done to understand the molecular mechanisms underlying its initiation and progression. In recent years, *O*-GlcNAcylation has been found to be particularly disturbed in oncogenic processes, irrespective of the stage or molecular process considered. In particular, because of its strategic position as a metabolic hub, this post-translational modification could play a role of switch between nutritional disorders and cancer. This Special Issue is an opportunity to take stock of current knowledge on the subject and to project research into the near future, which should shed new light into our understanding of the impact of a shaken *O*-GlcNAcylation homeostasis, related or not with the nutritional and environmental aspects, on cancer and anticancer therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)